130 related articles for article (PubMed ID: 11294506)
1. A sensitive mapping strategy for monitoring the reproducibility of glycan processing in an HIV vaccine, RGP-160, expressed in a mammalian cell line.
Tran NT; Taverna M; Merry AH; Chevalier M; Morgant G; Valentin C; Ferrier D
Glycoconj J; 2000 Jun; 17(6):401-6. PubMed ID: 11294506
[TBL] [Abstract][Full Text] [Related]
2. N-glycosylation at one rabies virus glycoprotein sequon influences N-glycan processing at a distant sequon on the same molecule.
Wojczyk BS; Takahashi N; Levy MT; Andrews DW; Abrams WR; Wunner WH; Spitalnik SL
Glycobiology; 2005 Jun; 15(6):655-66. PubMed ID: 15677380
[TBL] [Abstract][Full Text] [Related]
3. Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility.
Go EP; Irungu J; Zhang Y; Dalpathado DS; Liao HX; Sutherland LL; Alam SM; Haynes BF; Desaire H
J Proteome Res; 2008 Apr; 7(4):1660-74. PubMed ID: 18330979
[TBL] [Abstract][Full Text] [Related]
4. A multi-mode chromatographic method for the comparison of the N-glycosylation of a recombinant HIV envelope glycoprotein (gp160s-MN/LAI) purified by two different processes.
Taverna M; Nguyet TT; Valentin C; Level O; Merry T; Kolbe HV; Ferrier D
J Biotechnol; 1999 Feb; 68(1):37-48. PubMed ID: 10036769
[TBL] [Abstract][Full Text] [Related]
5. Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1.
Behrens AJ; Struwe WB; Crispin M
Expert Rev Proteomics; 2017 Oct; 14(10):881-890. PubMed ID: 28870097
[TBL] [Abstract][Full Text] [Related]
6. Synthetic carbohydrate antigens for HIV vaccine design.
Wang LX
Curr Opin Chem Biol; 2013 Dec; 17(6):997-1005. PubMed ID: 24466581
[TBL] [Abstract][Full Text] [Related]
7. Glycosylation of HIV-1 gp120 V3 loop: towards the rational design of a synthetic carbohydrate vaccine.
Sirois S; Touaibia M; Chou KC; Roy R
Curr Med Chem; 2007; 14(30):3232-42. PubMed ID: 18220757
[TBL] [Abstract][Full Text] [Related]
8. The glycosylation of human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) is important for the efficient intracellular transport of the envelope precursor gp160.
Fenouillet E; Jones IM
J Gen Virol; 1995 Jun; 76 ( Pt 6)():1509-14. PubMed ID: 7782780
[TBL] [Abstract][Full Text] [Related]
9. Stable secretion of a soluble, oligomeric form of rabies virus glycoprotein: influence of N-glycan processing on secretion.
Wojczyk B; Shakin-Eshleman SH; Doms RW; Xiang ZQ; Ertl HC; Wunner WH; Spitalnik SL
Biochemistry; 1995 Feb; 34(8):2599-609. PubMed ID: 7873541
[TBL] [Abstract][Full Text] [Related]
10. Recombinant Glycoprotein E of Varicella Zoster Virus Contains Glycan-Peptide Motifs That Modulate B Cell Epitopes into Discrete Immunological Signatures.
Nordén R; Nilsson J; Samuelsson E; Risinger C; Sihlbom C; Blixt O; Larson G; Olofsson S; Bergström T
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30813247
[TBL] [Abstract][Full Text] [Related]
11. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.
Parry C; McLain L; Dimmock NJ
AIDS Res Hum Retroviruses; 1994 Feb; 10(2):205-12. PubMed ID: 8198873
[TBL] [Abstract][Full Text] [Related]
12. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons.
Corbet S; Vinner L; Hougaard DM; Bryder K; Nielsen HV; Nielsen C; Fomsgaard A
AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1997-2008. PubMed ID: 11153083
[TBL] [Abstract][Full Text] [Related]
13. Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins.
Rovinski B; Rodrigues L; Cao SX; Yao FL; McGuinness U; Sia C; Cates G; Zolla-Pazner S; Karwowska S; Matthews TJ
AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1187-95. PubMed ID: 8573374
[TBL] [Abstract][Full Text] [Related]
14. Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope.
Pritchard LK; Harvey DJ; Bonomelli C; Crispin M; Doores KJ
J Virol; 2015 Sep; 89(17):8932-44. PubMed ID: 26085151
[TBL] [Abstract][Full Text] [Related]
15. Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs.
Khattar SK; Samal S; Devico AL; Collins PL; Samal SK
J Virol; 2011 Oct; 85(20):10529-41. PubMed ID: 21849467
[TBL] [Abstract][Full Text] [Related]
16. Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector.
Khattar SK; Samal S; LaBranche CC; Montefiori DC; Collins PL; Samal SK
PLoS One; 2013; 8(10):e78521. PubMed ID: 24098600
[TBL] [Abstract][Full Text] [Related]
17. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons.
Vinner L; Nielsen HV; Bryder K; Corbet S; Nielsen C; Fomsgaard A
Vaccine; 1999 Apr; 17(17):2166-75. PubMed ID: 10367950
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of glycan ratio of Chinese hamster ovary cell-cetuximab antigen-binding segment via rapid enzyme digestion with endo-
Cheng Q; Jia D; Zhang B; Xu J; Shao Z; Huang Y; Zou X
Se Pu; 2022 Feb; 40(2):175-181. PubMed ID: 35080164
[TBL] [Abstract][Full Text] [Related]
19. Functions of HIV envelope glycans.
Fenouillet E; Gluckman JC; Jones IM
Trends Biochem Sci; 1994 Feb; 19(2):65-70. PubMed ID: 8160267
[TBL] [Abstract][Full Text] [Related]
20. cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.
Dey AK; Cupo A; Ozorowski G; Sharma VK; Behrens AJ; Go EP; Ketas TJ; Yasmeen A; Klasse PJ; Sayeed E; Desaire H; Crispin M; Wilson IA; Sanders RW; Hassell T; Ward AB; Moore JP
Biotechnol Bioeng; 2018 Apr; 115(4):885-899. PubMed ID: 29150937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
